Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study.
Journal: Annals of the rheumatic diseases
Published: January 31, 2025
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry.
Journal: Journal of psoriasis and psoriatic arthritis
Published: April 01, 2023
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
Journal: Rheumatology and therapy
Published: February 09, 2022
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Journal: Rheumatology and therapy
Published: October 26, 2021
Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
Journal: Rheumatology and therapy
Published: August 09, 2021
Risk factors for changes in carotid intima media thickness and plaque over 5 years in women with systemic lupus erythematosus.
Journal: Lupus science & medicine
Published: July 26, 2021
A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
Journal: Rheumatology (Oxford, England)
Published: July 20, 2021
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Journal: Rheumatology and therapy
Published: February 05, 2021
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort.
Journal: Rheumatology (Oxford, England)
Published: October 12, 2020
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Journal: Annals of the rheumatic diseases
Published: August 13, 2020
Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.
Journal: RMD open
Published: February 04, 2019
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.
Journal: Lancet (London, England)
Published: May 22, 2018
Last Updated: 09/26/2026